Coronavirus disease 2019 in Latin American patients with multiple sclerosis.

Autor: Fragoso YD; Department of Post Graduate Studies, Universidade Metropolitana de Santos, Av. Conselheiro Nébias, 536, Santos, SP 11045-002, Brazil., Schiavetti I; Section of Biostatistics, Department of Health Sciences, University of Genoa, Genoa, Italy., Carmisciano L; Section of Biostatistics, Department of Health Sciences, University of Genoa, Genoa, Italy., Ponzano M; Section of Biostatistics, Department of Health Sciences, University of Genoa, Genoa, Italy., Steinberg J; Department of Neurology, Hospital Britanico, Buenos Aires, Argentina., Treviño-Frenk I; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Ciampi E; Department of Neurology, Hospital Sotero de Rio, Santiago, Chile., Vecino MCA; Department of Neurology, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil., Correa EP; Department of Neurology, Hospital Carlos Andrade Marin, Quito, Ecuador., Carcamo C; Department of Neurology, Universidad Catolica de Chile, Santiago, Chile., Gomes S; Department of Neurology, Hospital Beneficencia Portuguesa de Sao Paulo, Sao Paulo, SP, Brazil., Pimentel MLV; Department of Neurology, Santa Casa da Misericordia do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Santos GAC; Department of Neurology, Universidade Estacio de Sa and Universidade Federal Fluminense, Rio de Janeiro, RJ, Brazil., Vrech C; Department of Neurology, Sanatorio Allende, Cordoba, Argentina., Winckler TCA; Private Neurological Clinic, Curitiba, PR, Brazil., Sormani MP; Section of Biostatistics, Department of Health Sciences, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2021 Oct; Vol. 55, pp. 103173. Date of Electronic Publication: 2021 Jul 25.
DOI: 10.1016/j.msard.2021.103173
Abstrakt: Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associated to hospitalization and death. Despite the small sample size, this study highlights the awareness regarding therapeutic options for MS during the pandemic.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: